Prime Medicine (PRME) News
NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRME news summary
We found 8 recent headlines mentioning Prime Medicine (PRME): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Seeking Alpha, Nasdaq. PRME is making an outsized move today, down 7.55% at $3.55, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Prime Medicine GAAP EPS of -$0.22 beats by $0.02, revenue of $4.21M beats by $3.13M", was published by Seeking Alpha on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Prime Medicine headlines
- Prime Medicine GAAP EPS of -$0.22 beats by $0.02, revenue of $4.21M beats by $3.13MSeeking Alpha
- Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…GlobeNewswire
- Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected…GlobeNewswire
- Prime Medicine prices $125M public offering at $3.50 per shareSeeking Alpha
- Prime Medicine Announces Pricing of Public Offering of Common StockCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…GlobeNewswire
- Prime Medicine Announces Proposed $125.0 Million Public Offering of Common StockCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…GlobeNewswire
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…NasdaqIBRX, PRME
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyPRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.NasdaqAMRN, CORT, ALDX, PRME